• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Among patients with advanced ovarian carcinoma, who benefits from bevacizumab the most?在晚期卵巢癌患者中，谁从贝伐单抗中获益最大？
Ann Transl Med. 2023 Aug 30;11(10):367. doi: 10.21037/atm-23-903. Epub 2023 Mar 28.
2
Validation of the KELIM score as a predictor of response to neoadjuvant treatment in patients with advanced high grade serous ovarian cancer.验证 KELIM 评分作为预测晚期高级别浆液性卵巢癌患者新辅助治疗反应的指标。
Gynecol Oncol. 2022 Dec;167(3):417-422. doi: 10.1016/j.ygyno.2022.10.014. Epub 2022 Oct 27.
3
Olaparib: A Review as First-Line Maintenance Therapy in Advanced Ovarian Cancer.奥拉帕利：晚期卵巢癌一线维持治疗综述
Target Oncol. 2021 Nov;16(6):847-856. doi: 10.1007/s11523-021-00842-1. Epub 2021 Oct 8.
4
Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7).贝伐单抗用于新诊断的卵巢癌：高危疾病患者中的最佳候选者（ICON-7）
JNCI Cancer Spectr. 2020 Apr 4;4(3):pkaa026. doi: 10.1093/jncics/pkaa026. eCollection 2020 Jun.
5
Consensus statements and treatment algorithm to guide clinicians in the selection of maintenance therapy for patients with newly diagnosed, advanced ovarian carcinoma: Results of a Delphi study.指导临床医生为新诊断的晚期卵巢癌患者选择维持治疗的共识声明和治疗算法：一项 Delphi 研究的结果。
Gynecol Oncol. 2023 Aug;175:182-189. doi: 10.1016/j.ygyno.2023.05.065. Epub 2023 Jun 22.
6
Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10.早期 CA-125 纵向动力学（KELIM-PARP）模型的数学建模作为评估鲁卡帕利在 ARIEL2 和 STUDY10 复发性卵巢癌患者中的疗效的实用指标。
EBioMedicine. 2023 Mar;89:104477. doi: 10.1016/j.ebiom.2023.104477. Epub 2023 Feb 16.
7
FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer.FDA 批准概要：奥拉帕利单药治疗或联合贝伐珠单抗用于晚期卵巢癌患者的维持治疗。
Oncologist. 2021 Jan;26(1):e164-e172. doi: 10.1002/onco.13551. Epub 2020 Oct 20.
8
The Increasing Prognostic and Predictive Roles of the Tumor Primary Chemosensitivity Assessed by CA-125 Elimination Rate Constant K (KELIM) in Ovarian Cancer: A Narrative Review.通过CA-125消除率常数K（KELIM）评估的肿瘤原发化疗敏感性在卵巢癌中日益重要的预后和预测作用：一项叙述性综述
Cancers (Basel). 2021 Dec 25;14(1):98. doi: 10.3390/cancers14010098.
9
The Utilization of Bevacizumab in Patients with Advanced Ovarian Cancer: A Systematic Review of the Mechanisms and Effects.贝伐珠单抗在晚期卵巢癌患者中的应用：系统评价其机制和疗效。
Int J Mol Sci. 2022 Jun 21;23(13):6911. doi: 10.3390/ijms23136911.
10
Cost-effectiveness of Maintenance Therapy Based on Molecular Classification Following Treatment of Primary Epithelial Ovarian Cancer in the United States.基于分子分类的维持治疗在原发性上皮性卵巢癌治疗后的美国成本效益分析。
JAMA Netw Open. 2020 Dec 1;3(12):e2028620. doi: 10.1001/jamanetworkopen.2020.28620.

引用本文的文献

1
Precision Medicine in High-Grade Serous Ovarian Cancer: Targeted Therapies and the Challenge of Chemoresistance.高级别浆液性卵巢癌中的精准医学：靶向治疗与化疗耐药挑战
Int J Mol Sci. 2025 Mar 12;26(6):2545. doi: 10.3390/ijms26062545.

本文引用的文献

1
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.基于肿瘤内在化疗敏感性（KELIM）识别一线治疗中贝伐珠单抗获益最高的卵巢癌患者：GOG-0218 验证研究。
J Clin Oncol. 2022 Dec 1;40(34):3965-3974. doi: 10.1200/JCO.22.01207. Epub 2022 Oct 17.
2
Patients with low nicotinamide N-methyltransferase expression benefit significantly from bevacizumab treatment in ovarian cancer.低烟酰胺 N-甲基转移酶表达的卵巢癌患者从贝伐珠单抗治疗中显著获益。
BMC Cancer. 2021 Jan 14;21(1):67. doi: 10.1186/s12885-021-07785-w.
3
Bevacizumab for Newly Diagnosed Ovarian Cancers: Best Candidates Among High-Risk Disease Patients (ICON-7).贝伐单抗用于新诊断的卵巢癌：高危疾病患者中的最佳候选者（ICON-7）
JNCI Cancer Spectr. 2020 Apr 4;4(3):pkaa026. doi: 10.1093/jncics/pkaa026. eCollection 2020 Jun.
4
CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial.CA-125 消除率常数 K（KELIM）是卵巢癌患者化疗敏感性的标志物：来自 II 期 CHIVA 试验的结果。
Clin Cancer Res. 2020 Sep 1;26(17):4625-4632. doi: 10.1158/1078-0432.CCR-20-0054. Epub 2020 Mar 24.
5
Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer.贝伐珠单抗治疗卵巢癌的随机试验的最终总生存结果。
J Clin Oncol. 2019 Sep 10;37(26):2317-2328. doi: 10.1200/JCO.19.01009. Epub 2019 Jun 19.
6
Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses.肿瘤微血管密度作为贝伐单抗疗效的潜在预测标志物：妇科肿瘤学组-0218生物标志物分析
J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx066.
7
Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes.贝伐单抗可能对增殖性和间充质分子亚型的卵巢癌患者的预后有不同程度的改善。
Clin Cancer Res. 2017 Jul 15;23(14):3794-3801. doi: 10.1158/1078-0432.CCR-16-2196. Epub 2017 Feb 3.
8
Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial.新诊断卵巢癌女性使用或不使用贝伐单抗的标准化疗（ICON7）：一项3期随机试验的总生存结果
Lancet Oncol. 2015 Aug;16(8):928-36. doi: 10.1016/S1470-2045(15)00086-8. Epub 2015 Jun 23.
9
A phase 3 trial of bevacizumab in ovarian cancer.贝伐珠单抗治疗卵巢癌的 III 期临床试验。
N Engl J Med. 2011 Dec 29;365(26):2484-96. doi: 10.1056/NEJMoa1103799.
10
Incorporation of bevacizumab in the primary treatment of ovarian cancer.贝伐珠单抗在卵巢癌初始治疗中的应用。
N Engl J Med. 2011 Dec 29;365(26):2473-83. doi: 10.1056/NEJMoa1104390.

Among patients with advanced ovarian carcinoma, who benefits from bevacizumab the most?

作者信息

Babaier Abdulaziz, Ghatage Prafull

机构信息

Department of Obstetrics & Gynecology, Prince Sultant Military Medical City, Riyadh, Saudi Arabia.

Department of Gynecologic Oncology, Tom Baker Cancer Centre, Calgary, Alberta, Canada.

出版信息

Ann Transl Med. 2023 Aug 30;11(10):367. doi: 10.21037/atm-23-903. Epub 2023 Mar 28.

DOI:10.21037/atm-23-903
PMID:37675330
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10477662/
Abstract
摘要